News
Search EMA's news announcements
Emcitate can be used in patients of all ages
Oral medicine to treat two different conditions, rare von Hippel-Lindau disease and advanced clear cell renal cell carcinoma
Seventeen new medicines recommended for approval; another eight medicines recommended for extension of their therapeutic indications
Benefit of medicine used in Crohn’s disease no longer demonstrated
Positive opinion for extension of indication from age of six
Outcomes of the Committee for Veterinary Medicinal Products (CVMP) meeting
Doxycycline: currently available evidence not supporting link with risk of suicidality
Marketing authorisation holders can now use the platform to report shortages of centrally authorised human medicines.
EMA is advising marketing authorisation holders to submit type I variations for 2024 no later than 30 November 2024.
Use of opioid medicines with Mysimba may lead to serious side effects